Clinical Trial Update: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) [Phase 3]

View source ↗

Summary

Phase 3 MANIFEST-2 study of pelabresib (CPI-0610) in myelofibrosis has posted results as of Oct 28, 2024; the trial remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• Pelabresib (pelabresib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelofibrosis, Primary Myelofibrosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-10-28